Overview

Arimoclomol in Amyotropic Lateral Sclerosis

Status:
Completed

Trial end date:
2020-12-18

Target enrollment:

Participant gender:

Summary

A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)

Phase:

Phase 3

Details

Lead Sponsor:

Orphazyme